Abbott Laboratories (ABT) Stock Insights

ABT$115.51—
Medical - DevicesLarge Cap
Compare
Market cap$178.39BEnterprise value—Revenue (TTM)$48.23BMarket positionTop 25%

Score

45
Neutral
Value
44
Quality
52
Growth
38

Insights

  • Revenue by product
  • Revenue by region
Revenue by product
PeriodValue
FY2011Diagnostic Products: 4126000000.0, Established Pharmaceutical Products: 5413000000.0, Nutritional Products: 6006000000.0, Proprietary Pharmaceutical Products: 17022000000.0, Unallocated Amount to Segment: 2951000000.0, Vascular Products: 3333000000.0
FY2012Diagnostic Products: 4292000000.0, Established Pharmaceutical Products: 5121000000.0, Nutritional Products: 6471000000.0, Proprietary Pharmaceutical Products: 18012000000.0, Unallocated Amount to Segment: 2907000000.0, Vascular Products: 3071000000.0
FY2013Diagnostic Products: 4545000000.0, Established Pharmaceutical Products: 4974000000.0, Nutritional Products: 6740000000.0, Unallocated Amount to Segment: 2577000000.0, Vascular Products: 3012000000.0
FY2014Diagnostic Products: 4721000000.0, Established Pharmaceutical Products: 3118000000.0, Nutritional Products: 6953000000.0, Unallocated Amount to Segment: 2469000000.0, Vascular Products: 2986000000.0
FY2015Diagnostic Products: 4646000000.0, Established Pharmaceutical Products: 3720000000.0, Nutritional Products: 6975000000.0, Unallocated Amount to Segment: 2272000000.0, Vascular Products: 2792000000.0
FY2016Diagnostic Products: 4813000000.0, Established Pharmaceutical Products: 3859000000.0, Nutritional Products: 6899000000.0, Unallocated Amount to Segment: 2386000000.0, Vascular Products: 2896000000.0
FY2017Diagnostic Products: 5616000000.0, Established Pharmaceutical Products: 4287000000.0, Medical Devices: 8911000000.0, Nutritional Products: 6925000000.0, Unallocated Amount to Segment: 1651000000.0
FY2018Diagnostic Products: 7495000000.0, Established Pharmaceutical Products: 4422000000.0, Medical Devices: 9437000000.0, Nutritional Products: 7229000000.0, Unallocated Amount to Segment: 1995000000.0
FY2019Diagnostic Products: 7713000000.0, Established Pharmaceutical Products: 4486000000.0, Medical Devices: 12239000000.0, Nutritional Products: 7409000000.0, Unallocated Amount to Segment: 57000000.0
FY2020Diagnostic Products: 10805000000.0, Established Pharmaceutical Products: 4303000000.0, Medical Devices: 11787000000.0, Nutritional Products: 7647000000.0, Unallocated Amount to Segment: 66000000.0
FY2021Diagnostic Products: 15644000000.0, Established Pharmaceutical Products: 4718000000.0, Medical Devices: 14367000000.0, Nutritional Products: 8294000000.0
FY2022Diagnostic Products: 16584000000.0, Established Pharmaceutical Products: 4912000000.0, Medical Devices: 14687000000.0, Nutritional Products: 7459000000.0
FY2023Diagnostic Products: 9988000000.0, Established Pharmaceutical Products: 5066000000.0, Medical Devices: 16887000000.0, Nutritional Products: 8154000000.0
FY2024Diagnostic Products: 9341000000.0, Established Pharmaceutical Products: 5194000000.0, Medical Devices: 18986000000.0, Nutritional Products: 8413000000.0
FY2025Diagnostic Products: 8937000000.0, Established Pharmaceutical Products: 5536000000.0, Medical Devices: 21387000000.0, Nutritional Products: 8451000000.0
Revenue by region
PeriodValue
FY2010Non-US: 19973000000.0, UNITED STATES: 15194000000.0
FY2011Non-US: 22837000000.0, UNITED STATES: 16014000000.0
FY2012CANADA: 1253000000.0, D [E]: 1740000000.0, F [R]: 1167000000.0, I [N]: 933000000.0, I [T]: 1127000000.0, N [L]: 1883000000.0, Non-US: 10555000000.0, SPAIN: 942000000.0, UNITED STATES: 16784000000.0
FY2013B [R]: 470000000.0, C [H]: 792000000.0, C [N]: 1083000000.0, CANADA: 734000000.0, D [E]: 1070000000.0, F [R]: 680000000.0, I [N]: 922000000.0, I [T]: 726000000.0, N [L]: 960000000.0, Non-US: 5283000000.0, R [U]: 525000000.0, SPAIN: 413000000.0, UNITED STATES: 6269000000.0
FY2014B [R]: 508000000.0, C [H]: 707000000.0, C [N]: 1321000000.0, D [E]: 978000000.0, F [R]: 488000000.0, G [B]: 447000000.0, I [N]: 1009000000.0, I [T]: 436000000.0, N [L]: 788000000.0, Non-US: 5166000000.0, R [U]: 536000000.0, SPAIN: 310000000.0, UNITED STATES: 6123000000.0
FY2015B [R]: 381000000.0, C [H]: 784000000.0, C [N]: 1796000000.0, D [E]: 1004000000.0, F [R]: 375000000.0, G [B]: 430000000.0, I [N]: 1053000000.0, I [T]: 383000000.0, N [L]: 855000000.0, Non-US: 4880000000.0, R [U]: 483000000.0, UNITED STATES: 6270000000.0
FY2016B [R]: 410000000.0, C [H]: 766000000.0, C [N]: 1728000000.0, C [O]: 424000000.0, D [E]: 1044000000.0, G [B]: 377000000.0, I [N]: 1114000000.0, I [T]: 365000000.0, N [L]: 830000000.0, Non-US: 4989000000.0, R [U]: 554000000.0, UNITED STATES: 6486000000.0, V [N]: 434000000.0
FY2017B [R]: 541000000.0, C [H]: 841000000.0, C [N]: 2146000000.0, D [E]: 1366000000.0, F [R]: 628000000.0, G [B]: 498000000.0, I [N]: 1237000000.0, I [T]: 507000000.0, N [L]: 929000000.0, Non-US: 5741000000.0, R [U]: 664000000.0, UNITED STATES: 9673000000.0
FY2018C [H]: 1005000000.0, C [N]: 2311000000.0, D [E]: 1619000000.0, I [N]: 1333000000.0, N [L]: 930000000.0, Non-US: 11215000000.0, UNITED STATES: 10839000000.0
FY2019C [H]: 1068000000.0, C [N]: 2346000000.0, D [E]: 1751000000.0, I [N]: 1397000000.0, N [L]: 975000000.0, Non-US: 11534000000.0, UNITED STATES: 11398000000.0
FY2020C [H]: 1140000000.0, C [N]: 1965000000.0, D [E]: 2108000000.0, I [N]: 1323000000.0, N [L]: 1084000000.0, Non-US: 12580000000.0, UNITED STATES: 13022000000.0
FY2021C [H]: 1313000000.0, C [N]: 2392000000.0, CANADA: 1385000000.0, D [E]: 2572000000.0, I [N]: 1561000000.0, Non-US: 15515000000.0, UNITED STATES: 16642000000.0
FY2022C [H]: 1336000000.0, C [N]: 2133000000.0, CANADA: 1280000000.0, D [E]: 2340000000.0, I [N]: 1649000000.0, Non-US: 14841000000.0, UNITED STATES: 18142000000.0
FY2023C [H]: 1638000000.0, C [N]: 2253000000.0, D [E]: 2345000000.0, I [N]: 1750000000.0, N [L]: 1074000000.0, Non-US: 14084000000.0, UNITED STATES: 15452000000.0
FY2024C [H]: 1747000000.0, C [N]: 2113000000.0, D [E]: 2539000000.0, I [N]: 1817000000.0, N [L]: 1124000000.0, Non-US: 14846000000.0, UNITED STATES: 16323000000.0
FY2025C [H]: 1871000000.0, C [N]: 1907000000.0, D [E]: 2759000000.0, I [N]: 1871000000.0, Non-US: 15979000000.0, UNITED STATES: 17126000000.0

Abbott Laboratories (ABT) Stock Insights

ABT price $115.51 —

Ticker
ABT
Price
$115.51
Change
—
Market cap
$178.39B
P/E
38.30
Forward P/E
17.82
Dividend yield
2.18%
Beta
0.54
Sector
Healthcare
Industry
Medical - Devices
Stocklytics score
45
Value
44
Quality
52
Growth
38

Stocklytics score rationale: value 44, quality 52, growth 38.

AI Score 75. Abbott Laboratories has a solid market capitalization of approximately $199.9 billion and a stable beta of 0.54, indicating lower volatility. However, its high price-to-earnings ratio of 42.8 and a negative price-to-earnings growth ratio suggest that the stock may be overvalued relative to its earnings growth potential

Insights

Revenue by product
PeriodValue
FY2011Diagnostic Products: 4126000000.0, Established Pharmaceutical Products: 5413000000.0, Nutritional Products: 6006000000.0, Proprietary Pharmaceutical Products: 17022000000.0, Unallocated Amount to Segment: 2951000000.0, Vascular Products: 3333000000.0
FY2012Diagnostic Products: 4292000000.0, Established Pharmaceutical Products: 5121000000.0, Nutritional Products: 6471000000.0, Proprietary Pharmaceutical Products: 18012000000.0, Unallocated Amount to Segment: 2907000000.0, Vascular Products: 3071000000.0
FY2013Diagnostic Products: 4545000000.0, Established Pharmaceutical Products: 4974000000.0, Nutritional Products: 6740000000.0, Unallocated Amount to Segment: 2577000000.0, Vascular Products: 3012000000.0
FY2014Diagnostic Products: 4721000000.0, Established Pharmaceutical Products: 3118000000.0, Nutritional Products: 6953000000.0, Unallocated Amount to Segment: 2469000000.0, Vascular Products: 2986000000.0
FY2015Diagnostic Products: 4646000000.0, Established Pharmaceutical Products: 3720000000.0, Nutritional Products: 6975000000.0, Unallocated Amount to Segment: 2272000000.0, Vascular Products: 2792000000.0
FY2016Diagnostic Products: 4813000000.0, Established Pharmaceutical Products: 3859000000.0, Nutritional Products: 6899000000.0, Unallocated Amount to Segment: 2386000000.0, Vascular Products: 2896000000.0
FY2017Diagnostic Products: 5616000000.0, Established Pharmaceutical Products: 4287000000.0, Medical Devices: 8911000000.0, Nutritional Products: 6925000000.0, Unallocated Amount to Segment: 1651000000.0
FY2018Diagnostic Products: 7495000000.0, Established Pharmaceutical Products: 4422000000.0, Medical Devices: 9437000000.0, Nutritional Products: 7229000000.0, Unallocated Amount to Segment: 1995000000.0
FY2019Diagnostic Products: 7713000000.0, Established Pharmaceutical Products: 4486000000.0, Medical Devices: 12239000000.0, Nutritional Products: 7409000000.0, Unallocated Amount to Segment: 57000000.0
FY2020Diagnostic Products: 10805000000.0, Established Pharmaceutical Products: 4303000000.0, Medical Devices: 11787000000.0, Nutritional Products: 7647000000.0, Unallocated Amount to Segment: 66000000.0
FY2021Diagnostic Products: 15644000000.0, Established Pharmaceutical Products: 4718000000.0, Medical Devices: 14367000000.0, Nutritional Products: 8294000000.0
FY2022Diagnostic Products: 16584000000.0, Established Pharmaceutical Products: 4912000000.0, Medical Devices: 14687000000.0, Nutritional Products: 7459000000.0
FY2023Diagnostic Products: 9988000000.0, Established Pharmaceutical Products: 5066000000.0, Medical Devices: 16887000000.0, Nutritional Products: 8154000000.0
FY2024Diagnostic Products: 9341000000.0, Established Pharmaceutical Products: 5194000000.0, Medical Devices: 18986000000.0, Nutritional Products: 8413000000.0
FY2025Diagnostic Products: 8937000000.0, Established Pharmaceutical Products: 5536000000.0, Medical Devices: 21387000000.0, Nutritional Products: 8451000000.0
Revenue by region
PeriodValue
FY2010Non-US: 19973000000.0, UNITED STATES: 15194000000.0
FY2011Non-US: 22837000000.0, UNITED STATES: 16014000000.0
FY2012CANADA: 1253000000.0, D [E]: 1740000000.0, F [R]: 1167000000.0, I [N]: 933000000.0, I [T]: 1127000000.0, N [L]: 1883000000.0, Non-US: 10555000000.0, SPAIN: 942000000.0, UNITED STATES: 16784000000.0
FY2013B [R]: 470000000.0, C [H]: 792000000.0, C [N]: 1083000000.0, CANADA: 734000000.0, D [E]: 1070000000.0, F [R]: 680000000.0, I [N]: 922000000.0, I [T]: 726000000.0, N [L]: 960000000.0, Non-US: 5283000000.0, R [U]: 525000000.0, SPAIN: 413000000.0, UNITED STATES: 6269000000.0
FY2014B [R]: 508000000.0, C [H]: 707000000.0, C [N]: 1321000000.0, D [E]: 978000000.0, F [R]: 488000000.0, G [B]: 447000000.0, I [N]: 1009000000.0, I [T]: 436000000.0, N [L]: 788000000.0, Non-US: 5166000000.0, R [U]: 536000000.0, SPAIN: 310000000.0, UNITED STATES: 6123000000.0
FY2015B [R]: 381000000.0, C [H]: 784000000.0, C [N]: 1796000000.0, D [E]: 1004000000.0, F [R]: 375000000.0, G [B]: 430000000.0, I [N]: 1053000000.0, I [T]: 383000000.0, N [L]: 855000000.0, Non-US: 4880000000.0, R [U]: 483000000.0, UNITED STATES: 6270000000.0
FY2016B [R]: 410000000.0, C [H]: 766000000.0, C [N]: 1728000000.0, C [O]: 424000000.0, D [E]: 1044000000.0, G [B]: 377000000.0, I [N]: 1114000000.0, I [T]: 365000000.0, N [L]: 830000000.0, Non-US: 4989000000.0, R [U]: 554000000.0, UNITED STATES: 6486000000.0, V [N]: 434000000.0
FY2017B [R]: 541000000.0, C [H]: 841000000.0, C [N]: 2146000000.0, D [E]: 1366000000.0, F [R]: 628000000.0, G [B]: 498000000.0, I [N]: 1237000000.0, I [T]: 507000000.0, N [L]: 929000000.0, Non-US: 5741000000.0, R [U]: 664000000.0, UNITED STATES: 9673000000.0
FY2018C [H]: 1005000000.0, C [N]: 2311000000.0, D [E]: 1619000000.0, I [N]: 1333000000.0, N [L]: 930000000.0, Non-US: 11215000000.0, UNITED STATES: 10839000000.0
FY2019C [H]: 1068000000.0, C [N]: 2346000000.0, D [E]: 1751000000.0, I [N]: 1397000000.0, N [L]: 975000000.0, Non-US: 11534000000.0, UNITED STATES: 11398000000.0
FY2020C [H]: 1140000000.0, C [N]: 1965000000.0, D [E]: 2108000000.0, I [N]: 1323000000.0, N [L]: 1084000000.0, Non-US: 12580000000.0, UNITED STATES: 13022000000.0
FY2021C [H]: 1313000000.0, C [N]: 2392000000.0, CANADA: 1385000000.0, D [E]: 2572000000.0, I [N]: 1561000000.0, Non-US: 15515000000.0, UNITED STATES: 16642000000.0
FY2022C [H]: 1336000000.0, C [N]: 2133000000.0, CANADA: 1280000000.0, D [E]: 2340000000.0, I [N]: 1649000000.0, Non-US: 14841000000.0, UNITED STATES: 18142000000.0
FY2023C [H]: 1638000000.0, C [N]: 2253000000.0, D [E]: 2345000000.0, I [N]: 1750000000.0, N [L]: 1074000000.0, Non-US: 14084000000.0, UNITED STATES: 15452000000.0
FY2024C [H]: 1747000000.0, C [N]: 2113000000.0, D [E]: 2539000000.0, I [N]: 1817000000.0, N [L]: 1124000000.0, Non-US: 14846000000.0, UNITED STATES: 16323000000.0
FY2025C [H]: 1871000000.0, C [N]: 1907000000.0, D [E]: 2759000000.0, I [N]: 1871000000.0, Non-US: 15979000000.0, UNITED STATES: 17126000000.0

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener